Table 2:
Treatment Characteristics
| All Patients (n=23) | Chemo-sensitive Patients (n=8) | Chemo-refractory Patients (n=15) | ||
|---|---|---|---|---|
| No. patients (%) mean (st dev) median [range] | No. patients (%) mean (st dev) median [range] | No. patients (%) mean (st dev) median [range] | p-value | |
| First-line ChT | ||||
| R-CHOP | 19 (82.6%) | 6 (75.0%) | 13 (86.7%) | 0.589** |
| DA-R-EPOCH | 4 (17.4%) | 2 (25.0%) | 2 (13.3%) | |
| ChT regimens before RT | 1 [1–4] | 1 [1–1] | 2 [1–4] | 0.008* |
| SCT before RT | 3 (13.0%) | 0 (0.0%) | 3 (20.0%) | 0.526** |
| Residual mass (cm) | 6.1 [2.1–17.3] | 6.1 [3.5–11.1] | 6.2 [2.1–17.3] | 0.825* |
| 5PS Prior to RT | ||||
| 1–3 | 11 (47.8%) | 8 (100%) | 3 (20.0%) | <0.001*** |
| 4 | 2 (8.7%) | 0 (0.0%) | 2 (13.3%) | |
| 5 | 10 (43.5%) | 0 (0.0%) | 10 (66.7%) | |
| RT Dose (Gy) | 40.0 [16.2–49.4] | 30.6 [16.2–36.0] | 42 [30.6–49.4] | <0.001* |
| Dose >= 40 Gy | 13 (56.5%) | 0 (0.0%) | 13 (86.7%) | |
| Any Boost | 5 (21.7%) | 0 (0.0%) | 5 (33.3%) | 0.122** |
| DIBH utilized | 11 (47.8%) | 4 (50.0%) | 7 (46.2%) | >0.999** |
| Mean Right Kidney Dose (Gy) | 5.4 (3.7) | 4.6 (2.8) | 5.9 (4.2) | 0.441*** |
| Mean Left Kidney Dose (Gy) | 6.8 (3.8) | 5.2 (2.0) | 7.6 (4.4) | 0.088*** |
| Mean Liver Dose (Gy)Ɨ | 3.4 (2.4) | 3.5 (2.1) | 3.3 (2.6) | 0.894*** |
| Post-RT therapy | 2 (25%) | 7 (46.7%) | 0.400** | |
| Maintenance Rituxan | 2 (25%) | 0 (0.0%) | ||
| Allogeneic SCT | 0 (0.0%) | 4 (26.7%) | ||
| CAR-T cell therapy | 0 (0.0%) | 2 (13.3%) | ||
| Other salvage ChT | 0 (0.0%) | 1 (6.7%) | ||
*
Mann-Whitney U Test
**
Fisher’s Exact Test
***
Independent t-test
Ɨ
Mean Liver Dose only available for 16 patients total (5 chemo-sensitive and 11 chemo-refractory) Abbreviations: ChT, chemotherapy; R-CHOP, rituximab cyclophosphamide doxorubicin vincristine prednisone combination chemotherapy; DA-R-EPOCH, dose-adjusted etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin, rituximab; RT = radiation therapy; SCT = stem cell transplant; CAR-T = Chimeric antigen receptor T-cell therapy; DIBH = deep inspiration breath hold;